NCT06325683 2026-04-21
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Suspended
Clinical Trials
18 trialsNCT06894225 2026-04-20
Proof-of-Concept Study of ACT001 in Adult Patients With Recurrent Glioblastoma Harbouring STAT3-High Signature
National Neuroscience Institute
Phase 2 Suspended
NCT05960773 2026-04-17
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 2 Suspended
NCT07025512 2026-04-16
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
M.D. Anderson Cancer Center
Phase 2 Suspended
NCT03575611 2026-04-15
Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Suspended
NCT06538389 2026-04-15
High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer
City of Hope Medical Center
Phase 2 Suspended
NCT07403136 2026-04-15
Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC
Fudan University
Phase 2 Suspended
NCT03952598 2026-04-14
Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy
National Institutes of Health Clinical Center (CC)
Phase 2 Suspended
NCT03375307 2026-04-13
Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes
National Cancer Institute (NCI)
Phase 2 Suspended
NCT04616560 2026-04-13
Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma
National Cancer Institute (NCI)
Phase 2 Suspended
NCT05223036 2026-04-13
Testing Obeticholic Acid for Familial Adenomatous Polyposis
National Cancer Institute (NCI)
Phase 2 Suspended
NCT05554380 2026-04-13
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Suspended
NCT05955261 2026-04-13
A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia
St. Jude Children's Research Hospital
Phase 2 Suspended
NCT05420948 2026-04-09
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
University of Chicago
Phase 2 Suspended
NCT05751668 2026-04-07
Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II)
Alliance for Clinical Trials in Oncology
Phase 2 Suspended
NCT05903092 2026-04-07
MOZART
Hoosier Cancer Research Network
Phase 2 Suspended
NCT04803201 2026-04-02
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Suspended
NCT04747912 2026-03-30
Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
University of Chicago
Phase 2 Suspended